Postoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: a preferential benefit for squamous cell carcinoma

Tian Cuimeng; Liu Guimei; Xu Yongxiang; Xia Guangrong; Zhang Tongmei; Huang Jiaqiang; Jiang Hui; Ming Wang Ji; Li Baolan

doi:10.2478/raon-2020-0070

Radiology and Oncology (Dec 2020)

Postoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: a preferential benefit for squamous cell carcinoma

Tian Cuimeng,
Liu Guimei,
Xu Yongxiang,
Xia Guangrong,
Zhang Tongmei,
Huang Jiaqiang,
Jiang Hui,
Ming Wang Ji,
Li Baolan

Affiliations

Tian Cuimeng: Department of Radiation Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute / Beijing Chest Hospital, Capital Medical University, Beijing, China
Liu Guimei: Department of Radiation Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute / Beijing Chest Hospital, Capital Medical University, Beijing, China
Xu Yongxiang: Department of Radiation Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute / Beijing Chest Hospital, Capital Medical University, Beijing, China
Xia Guangrong: Department of Radiation Oncology, Beijing Tuberculosis and Thoracic Tumor Research Institute / Beijing Chest Hospital, Capital Medical University, Beijing, China
Zhang Tongmei: Department of General Medicine, Beijing Tuberculosis and Thoracic Tumor Research Institute / Beijing Chest Hospital, Capital Medical University, Beijing, China
Huang Jiaqiang: Department of Cellular and Molecular Biology, Beijing Tuberculosis and Thoracic Tumor Research Institute / Beijing Chest Hospital, Capital Medical University, Beijing, China
Jiang Hui: Division of Technology, Beijing Tuberculosis and Thoracic Tumor Research Institute / Beijing Chest Hospital, Capital Medical University, Beijing, China
Ming Wang Ji: Laboratory of Cancer ImmunoMetabolism, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, USA
Li Baolan: Department of General Medicine, Beijing Tuberculosis and Thoracic Tumor Research Institute / Beijing Chest Hospital, Capital Medical University, Beijing, China

DOI: https://doi.org/10.2478/raon-2020-0070
Journal volume & issue: Vol. 55, no. 1
pp. 66 – 76

Abstract

Read online

The beneficial effect of postoperative radiotherapy (PORT) on completely resected pathological IIIA-N2 (pIIIA-N2) non-small cell lung cancer (NSCLC) has been a subject of interest with controversy. The aim of the study was to distinguish the clinical efficacy of PORT on lung adenocarcinoma (LADC) and lung squamous cell carcinoma (LSCC) among pIIIA-N2 NSCLC.

Published in Radiology and Oncology

ISSN: 1581-3207 (Online)
Publisher: Sciendo
Country of publisher: Slovenia
LCC subjects: Medicine: Medicine (General): Medical physics. Medical radiology. Nuclear medicine
Website: https://sciendo.com/journal/RAON

About the journal

Abstract

Keywords